The Top 5 Biosimilar Articles for the Week of May 9

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 9, 2022.

Number 5: A report on biosimilar uptake and existing policies signaled that policy makers should proceed with caution when establishing new policies to boost biosimilar utilization and savings, as many patients and providers still have concerns on their usage.

Number 4: Biosimilar manufacturers should consider working together to overcome some of the barriers that prevent biosimilars from entering the market and obtaining market share, according to Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board.

Number 3: Amgen’s earnings report for the first quarter of 2022 revealed that as some of its biosimilars experienced increased sales, its sales for reference products that are facing biosimilar competition decreased.

Number 2: A Vanderbilt University health policy researcher called for modernization of Medicare policies to control or cap out-of-pocket costs for seniors, as more high-cost cancer drugs are managed under the Part D program.

Number 1: During the Coherus Biosciences earnings call, the company announced that it was terminating its licensing agreement with Innovent Biologics for Byvasda, a bevacizumab biosimilar candidate referencing Avastin.

To read all of these articles and more, visit centerforbiosimilars.com.